4.6 Article

Using the rate of bacterial clearance determined by real-time polymerase chain reaction as a timely surrogate marker to evaluate the appropriateness of antibiotic usage in critical patients with Acinetobacter baumannii bacteremia

期刊

CRITICAL CARE MEDICINE
卷 40, 期 8, 页码 2273-2280

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCM.0b013e3182515190

关键词

Acinetobacter baumannii; appropriate antibiotics; bacteremia; critical care; rate of bacterial clearance

资金

  1. National Science Council Taiwan [NSC-95-2745-B-002-007, NSC-100-2314-B-002-117]
  2. Department of Health Taiwan [DOH100-TD-B-111-001]

向作者/读者索取更多资源

Objective: Bacteremia caused by Acinetobacter baumannii is becoming more frequent among critically ill patients, and has been associated with high mortality and prolonged hospital stay. Multidrug resistance and delay in blood culture have been shown to be significant barriers to appropriate antibiotic treatment. Quantitative polymerase chain reaction assays were recently used to monitor bacterial loads; we hypothesized that the rate of bacterial clearance determined by quantitative polymerase chain reaction can be used as a timely surrogate marker to evaluate the appropriateness of antibiotic usage. Design: Prospective observational study. Setting: University hospital and research laboratory. Patients: Patients with culture-proven A. baumannii bacteremia in the intensive care units were prospectively enrolled from April 2008 to February 2009. Interventions: Plasmid Oxa-51/pCRII-TOPO, which contained a 431-bp fragment of the A. baumannii-specific Oxa-51 gene in a pCRII-TOPO vector, was used as the standard. Sequential bacterial DNA loads in the blood were measured by a quantitative polymerase chain reaction assay. Measurements and Main Results: We enrolled 51 patients with A. baumannii bacteremia, and examined 318 sequential whole blood samples. The initial mean bacterial load was 2.15 log copies/mL, and the rate of bacterial clearance was 0.088 log copies/mL/day. Multivariate linear regression using the generalized estimation equation approach revealed that the use of immunosuppressants was an independent predictor for slower bacterial clearance (coefficient, 1.116; p < .001), and appropriate antibiotic usage was an independent predictor for more rapid bacterial clearance (coefficient, -0.995; p < .001). Patients with a slower rate of bacterial clearance experienced higher in-hospital mortality (odds ratio, 2.323; p = .04) Conclusions: Immunosuppression and appropriate antibiotic usage were independent factors affecting the rate of clearance of A. baumannii bacteremia in critical patients. These findings highlight the importance of appropriate antibiotic usage and development of effective antibiotics against A. baumannii in an era of emerging antibiotic resistance. The rate of bacterial clearance could serve as a timely surrogate marker for evaluating the appropriateness of antibiotics. (Crit Care Med 2012; 40:2273-2280)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Infectious Diseases

Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens

Guan-Jhou Chen, Hsin-Yun Sun, Ling-Ya Chen, Szu-Min Hsieh, Wang-Hui Sheng, Wang-Da Liu, Yu-Chung Chuang, Yu-Shan Huang, Kuan-Yin Lin, Pei-Ying Wu, Hsi-Yen Chang, Yu-Zhen Luo, Yi-Ching Su, Wen-Chun Liu, Sui-Fang Chang, Sui-Yuan Chang, Chien-Ching Hung

Summary: This study investigated the incidence and impact of low-level viraemia (LLV) among HIV-infected patients receiving second-generation integrase strand transferase inhibitors. The results showed that the risk of developing LLV or virologic failure (VF) was similar after switching to either dolutegravir- or bictegravir-based antiretroviral therapy (ART) in virally suppressed patients. Pre-existing resistance-associated mutations or LLV events were not associated with subsequent VF.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)

Article Medicine, General & Internal

Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan

Wang-Huei Sheng, Chung-Cheng Wang, Ching -Chi Chu, Yueh-Juh Lin, Sui-Yuan Chang, Shan-Chwen Chang

Summary: We reported the clinical and immunological effects of undiluted BNT162b2 vaccine inoculation in 25 recipients. The most common adverse reactions were injection site pain, fever, fatigue, chest tightness, and dizziness. Laboratory abnormalities included anemia and elevated liver transaminase level. These adverse reactions and abnormalities were mild and spontaneously recovered within a few weeks. The spike IgG titers significantly increased after a booster dose of BNT162b2.

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2023)

Article Medicine, Research & Experimental

Daptomycin area under the curve to minimum inhibitory concentration ratio by broth microdilution for predicting the outcome of vancomycin-resistant Enterococcus bloodstream infection

Yu-Chung Chuang, Hsin-Yi Lin, Jann-Tay Wang, Jia-Ling Yang, Chi-Ying Lin, Sung-Hsi Huang, Yee-Chun Chen, Shan-Chwen Chang

Summary: This retrospective cohort study compares different daptomycin minimum inhibitory concentration (MIC) testing methods for predicting clinical outcome of vancomycin-resistant enterococcus (VRE) bacteremia. The results indicate that the dichotomized threshold for free drug area under the concentration-time curve to MIC ratio (fAUC/MIC) for broth microdilution (BMD) is the best predictor of mortality.

BIOMEDICINE & PHARMACOTHERAPY (2022)

Article Immunology

In vitro susceptibility of common Enterobacterales to eravacycline in Taiwan

Chun-Fu Huang, Jann-Tay Wang, Yu -Chung Chuang, Wang-Huei Sheng, Yee -Chun Chen

Summary: This study evaluated the in vitro activity of eravacycline against common Enterobacterales and found that it exhibited high susceptibility rates against certain strains, making it a potential therapeutic option.

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2023)

Article Medicine, General & Internal

Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination with a twelve-week interval

Wang-Huei Sheng, Sui-Yuan Chang, Ming-Ju Hsieh, Si-Man Ieong, Shan-Chwen Chang

Summary: The appropriate interval between heterologous prime adenoviral vectored vaccination and boost mRNA vaccination remains unclear. We recruited 100 adult participants to receive a prime adenoviral vectored vaccine (ChAdOx1, AstraZeneca) and a boost mRNA vaccine (mRNA-1273, Moderna) 12 weeks apart and checked their serum SARS-CoV-2 anti-spike IgG titers and neutralizing antibody titers against B.1.1.7 (alpha) and B.1.617.2 (delta) variants on the 28th day after the boost dose. Results were compared with our previous study cohorts who received the same prime-boost vaccinations at 4-and 8-week intervals. Compared to other heterologous vaccination groups, the 12-week interval group had higher neutralizing antibody titers against SARS-CoV-2 variants than the 4-week interval group and was similar to the 8-week interval group at day 28. Adverse reactions after the boost dose were mild and transient. Our results support deploying viral vectored and mRNA vaccines in a flexible schedule with intervals from 8 to 12 weeks.

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2023)

Article Medicine, General & Internal

Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine

Wang-Huei Sheng, Si-Man Ieong, Pin-Hung Lin, Ming-Ju Hsieh, Hung-Chih Yang, Ching-Fu Pan, Tai-Ling Chao, Sui-Yuan Chang, Shan-Chwen Chang

Summary: The study investigated the immunogenicity and adverse events of the third dose of mRNA vaccines in healthy adults. The results showed that the third dose mRNA COVID-19 vaccines markedly enhanced cellular and humoral responses and were safe. Immunological responses and adverse events were higher in individuals receiving the full-dose mRNA-1273 vaccine compared to other groups.

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2023)

Article Infectious Diseases

Risk factors for mortality after linezolid treatment of Enterococcus bloodstream infection

Szu-Ting Huang, Jia-Ling Yang, Chi-Ying Lin, Sung-Hsi Hang, Jann-Tay Wang, Yu-Chung Chuang, Yee-Chun Chen, Shan-Chwen Chang

Summary: This study analyzed the risk factors affecting the treatment outcome of linezolid for vancomycin-resistant Enterococcus bloodstream infection. The study found that the linezolid minimum inhibitory concentration and concentration-time curve/MIC were not associated with mortality, while the linezolid dose per body weight, body height, and the interaction between them were independent risks for mortality. In conclusion, the clinical outcomes of linezolid treatment for vancomycin-resistant Enterococcus bloodstream infection are associated with the dose and body height.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2023)

Article Medicine, General & Internal

Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations

Aristine Cheng, Ming-Ju Hsieh, Sui-Yuan Chang, Si-Man Ieong, Chien-Yu Cheng, Wang-Huei Sheng, Shan-Chwen Chang

Summary: This study investigated whether adverse reactions to different COVID-19 vaccines reliably predict immune responses. The results showed that participants who reported local erythema, swelling, pain, as well as systemic fever, chills, headache, myalgia, arthralgia, and fatigue had significantly higher antibody levels at days 14 and 28 compared to those who did not report local or systemic reactogenicity.

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2023)

Article Infectious Diseases

The Combination of Daptomycin with Fosfomycin is More Effective than Daptomycin Alone in Reducing Mortality of Vancomycin-Resistant Enterococcal Bloodstream Infections: A Retrospective, Comparative Cohort Study

Tai-Chung Tseng, Yu-Chung Chuang, Jia-Ling Yang, Chi-Ying Lin, Sung-Hsi Huang, Jann-Tay Wang, Yee-Chun Chen, Shan-Chwen Chang

Summary: In this study, combination therapy with high-dose daptomycin and fosfomycin was found to improve the survival rate of patients with vancomycin-resistant enterococcus bloodstream infection compared to daptomycin monotherapy. The survival benefit was most pronounced for patients with fosfomycin MIC ≤64 mg/L and a low Pitt bacteremia score.

INFECTIOUS DISEASES AND THERAPY (2023)

Article Immunology

A Randomized Clinical Trial of 1-Dose vs Accelerated 2-Dose Schedule for Hepatitis A Virus (HAV) Revaccination Among People With Human Immunodeficiency Virus Who Were Nonresponders or Had Seroreversion After Primary HAV Vaccination

Guan-Jhou Chen, Hsin-Yun Sun, Kuan-Yin Lin, Szu-Min Hsieh, Yu-Chung Chuang, Wang-Da Liu, Yu-Shan Huang, Sung-Ching Pan, Un-In Wu, Aristine Cheng, Yi-Chia Huang, Cheng-Hsin Wu, Yi-Ching Su, Wen-Chun Liu, Sui-Yuan Chang, Chien-Ching Hung

Summary: For people with human immunodeficiency virus (PWH) who had no response or seroreversion after primary hepatitis A virus (HAV) vaccination, an accelerated 2-dose revaccination (vs 1-dose) produced higher antibody titers and elicited a higher serological response rate at week 48 for nonresponders.

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

Original Article Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide

Ling-Ya Chen, Hsin-Yun Sun, Yu -Chung Chuang, Wang -Da Liu, Kuan-Yin Lin, Hsi -Yen Chang, Yu-Zhen Luo, Pei-Ying Wu, Yi-Ching Su, Wen -Chun Liu, Chien -Ching Hung

Summary: This study aimed to investigate the improvement in HIV-related symptom burden among people living with HIV (PLWH) who switched to the co-formulated bic-tegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) in a real-world setting. The results showed that after 48 weeks of switching to B/F/TAF, there was a significant reduction in the prevalence and bothersomeness of certain symptoms.

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2023)

Article Immunology

Optimal Frequency of Hepatitis C Virus (HCV) RNA Testing for Detection of Acute HCV Infection Among At-risk People With Human Immunodeficiency Virus: A Multicenter Study

Hsin-Yun Sun, Bo-Huang Liou, Tun-Chieh Chen, Chia-Jui Yang, Sung-Hsi Huang, Po-Liang Lu, Chung-Hao Huang, Mao-Song Tsai, Shu-Hsing Cheng, Nan-Yao Lee, Wen-Chien Ko, Yen-Hsu Chen, Wang-Da Liu, Shang-Yi Lin, Shih-Ping Lin, Po-Lin Chen, Ling-Shan Syue, Yu-Shan Huang, Yu-Chung Chuang, Cheng-Bin Chen, Ya-Ting Chang, Yuan-Ti Lee, Szu-Min Hsieh, Li-Hsin Su, Chien-Yu Cheng, Chien-Ching Hung

Summary: Using 3-stage pooled-plasma hepatitis C virus (HCV) RNA testing performed quarterly among at-risk people with human immunodeficiency virus (PWH), we found that if testing had been performed every 6 or 12 months, 58.6%-91.7% of PWH who recently acquired HCV would be delayed for diagnosis and might contribute to onward HCV transmission with longer durations.

OPEN FORUM INFECTIOUS DISEASES (2023)

Article Microbiology

Immune Reconstitution Inflammatory Syndrome in People Living with HIV Who Presented with Interstitial Pneumonitis: an Emerging Challenge in the Era of Rapid Initiation of Antiretroviral Therapy

Kai-Hsiang Chen, Wang-Da Liu, Hsin-Yun Sun, Kuan-Yin Lin, Szu-Min Hsieh, Wang-Huei Sheng, Yu-Chung Chuang, Yu-Shan Huang, Aristine Cheng, Chien-Ching Hung

Summary: Limited studies have been conducted on immune reconstitution inflammatory syndrome (IRIS) in people living with HIV (PLWH) who present with interstitial pneumonitis (IP), particularly in the era of rapid antiretroviral therapy (ART) initiation with integrase strand-transfer inhibitor (INSTI)-containing regimens. A retrospective study identified PLWH who were diagnosed with IP and initiated ART within 30 days. The study found a high rate of IRIS and associations with baseline immune depletion, rapid decline of plasma HIV RNA load, and rapid initiation of ART.

MICROBIOLOGY SPECTRUM (2023)

Article Immunology

Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound

Guan-Jhou Chen, Hsin-Yun Sun, Sui-Yuan Chang, Szu-Min Hsieh, Wang-Hui Sheng, Yu-Chung Chuang, Yu-Shan Huang, Kuan-Yin Lin, Wen-Chun Liu, Yi-Ching Su, Chien-Ching Hung

Summary: This study aimed to investigate the virologic suppression effectiveness of switching to dolutegravir-based regimens or BIC/FTC/TAF among HIV-infected individuals who experienced viral rebound during other antiretroviral therapy. The results showed that within the first 48 weeks after switching, both dolutegravir-based regimens and BIC/FTC/TAF could achieve viral suppression in approximately four-fifths of the patients, and pre-existing NRTI-related resistance-associated mutations did not have a negative impact on the effectiveness.

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2023)

Article Multidisciplinary Sciences

Tracking gut microbiome and bloodstream infection in critically ill adults

Christopher H. Gu, Layla A. Khatib, Ayannah S. Fitzgerald, Jevon Graham-Wooten, Caroline A. Ittner, Scott Sherrill-Mix, Yuchung Chuang, Laurel J. Glaser, Nuala J. Meyer, Frederic D. Bushman, Ronald G. Collman

Summary: This study used sequencing analysis to investigate the relationship between gut microbiome and bloodstream infection in critically ill patients. The results showed that gut microbiome constituents matching the bloodstream infection species were present in half of the cases, with strain-level identity depending on the relative abundance of the species in the gut.

PLOS ONE (2023)

暂无数据